1. Home
  2. SMHI vs MDXH Comparison

SMHI vs MDXH Comparison

Compare SMHI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEACOR Marine Holdings Inc.

SMHI

SEACOR Marine Holdings Inc.

HOLD

Current Price

$6.00

Market Cap

179.4M

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.53

Market Cap

167.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMHI
MDXH
Founded
1989
2003
Country
United States
Belgium
Employees
N/A
N/A
Industry
Marine Transportation
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
179.4M
167.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SMHI
MDXH
Price
$6.00
$3.53
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
110.6K
114.5K
Earning Date
10-29-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$245,311,000.00
$103,069,000.00
Revenue This Year
N/A
$23.34
Revenue Next Year
$8.81
$22.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.68
52 Week Low
$3.63
$1.35
52 Week High
$7.88
$5.33

Technical Indicators

Market Signals
Indicator
SMHI
MDXH
Relative Strength Index (RSI) 34.37 50.37
Support Level $6.05 $3.20
Resistance Level $6.39 $3.58
Average True Range (ATR) 0.33 0.18
MACD -0.12 0.04
Stochastic Oscillator 16.28 85.42

Price Performance

Historical Comparison
SMHI
MDXH

About SMHI SEACOR Marine Holdings Inc.

Seacor Marine Holdings Inc provides marine and support transportation services to offshore energy facilities globally. The company operates and manages a diverse fleet of offshore support vessels that deliver cargo and personnel to offshore installations, including wind farms, handle anchors, and mooring equipment for offshore rigs and platforms. Its geographical segment includes the United States (Gulf of Mexico), Africa and Europe, Middle East and Asia, and Latin America.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: